Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers
Standard
Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. / Dum, David; Menz, Anne; Völkel, Cosima; De Wispelaere, Noémi; Hinsch, Andrea; Gorbokon, Natalia; Lennartz, Maximilian; Luebke, Andreas M; Hube-Magg, Claudia; Kluth, Martina; Fraune, Christoph; Möller, Katharina; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Marx, Andreas H; Simon, Ronald; Burandt, Eike; Krech, Till.
in: EXP MOL PATHOL, Jahrgang 126, 104762, 06.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers
AU - Dum, David
AU - Menz, Anne
AU - Völkel, Cosima
AU - De Wispelaere, Noémi
AU - Hinsch, Andrea
AU - Gorbokon, Natalia
AU - Lennartz, Maximilian
AU - Luebke, Andreas M
AU - Hube-Magg, Claudia
AU - Kluth, Martina
AU - Fraune, Christoph
AU - Möller, Katharina
AU - Bernreuther, Christian
AU - Lebok, Patrick
AU - Clauditz, Till S
AU - Jacobsen, Frank
AU - Sauter, Guido
AU - Uhlig, Ria
AU - Wilczak, Waldemar
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Marx, Andreas H
AU - Simon, Ronald
AU - Burandt, Eike
AU - Krech, Till
N1 - Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8.7% weak, 5.9% moderate, 37% strong) and CK20 positivity in 23% (5.1% weak, 3.4% moderate, 15% strong) of interpretable tumors. Of 8390 positive tumors, 1181 (14%) showed positivity for CK7 and CK20, 5380 (64%) showed positivity for CK7 alone, and 1829 (22%) showed positivity for CK20 alone. CK20 predominated in gastrointestinal tract, urothelial and Merkel cell carcinomas. CK7 was usually negative in prostate cancer and colorectal cancer. Combined evaluation of CK7/CK20 revealed the best diagnostic utility in CK20 positive tumors, where CK7 negativity is often linked to colorectal origin while CK7 positivity argues for urothelial origin or mucinous ovarian cancer. Associations with unfavorable tumor features were found for cytokeratin 7 loss in breast cancer of no special type, urothelial and renal cell carcinomas, for CK7 overexpression in high-grade serous ovarian and gastric cancer, and for CK20 overexpression in urothelial carcinoma. CK20 loss was linked to MSI in gastric (p = 0.0291) and colorectal adenocarcinoma (p < 0.0001). These analyses provide comprehensive data on the frequency of CK7 and CK20 immunostaining - alone or in combination - in human cancers. These data facilitate interpretation of CK7/CK20 immunostaining in cancers.
AB - Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8.7% weak, 5.9% moderate, 37% strong) and CK20 positivity in 23% (5.1% weak, 3.4% moderate, 15% strong) of interpretable tumors. Of 8390 positive tumors, 1181 (14%) showed positivity for CK7 and CK20, 5380 (64%) showed positivity for CK7 alone, and 1829 (22%) showed positivity for CK20 alone. CK20 predominated in gastrointestinal tract, urothelial and Merkel cell carcinomas. CK7 was usually negative in prostate cancer and colorectal cancer. Combined evaluation of CK7/CK20 revealed the best diagnostic utility in CK20 positive tumors, where CK7 negativity is often linked to colorectal origin while CK7 positivity argues for urothelial origin or mucinous ovarian cancer. Associations with unfavorable tumor features were found for cytokeratin 7 loss in breast cancer of no special type, urothelial and renal cell carcinomas, for CK7 overexpression in high-grade serous ovarian and gastric cancer, and for CK20 overexpression in urothelial carcinoma. CK20 loss was linked to MSI in gastric (p = 0.0291) and colorectal adenocarcinoma (p < 0.0001). These analyses provide comprehensive data on the frequency of CK7 and CK20 immunostaining - alone or in combination - in human cancers. These data facilitate interpretation of CK7/CK20 immunostaining in cancers.
KW - Biomarkers, Tumor/metabolism
KW - Carcinoma, Transitional Cell/genetics
KW - Colorectal Neoplasms/genetics
KW - Humans
KW - Intermediate Filament Proteins/genetics
KW - Keratin-20/genetics
KW - Keratin-7/genetics
KW - Keratins/analysis
KW - Male
KW - Urinary Bladder Neoplasms/genetics
U2 - 10.1016/j.yexmp.2022.104762
DO - 10.1016/j.yexmp.2022.104762
M3 - SCORING: Journal article
C2 - 35390310
VL - 126
JO - EXP MOL PATHOL
JF - EXP MOL PATHOL
SN - 0014-4800
M1 - 104762
ER -